Compare Amphastar Pharmaceuticals Inc (AMPH) vs OneSpan Inc (OSPN) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

OneSpan (OSPN) trades at $15.17, down slightly by 0.26% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 28.47% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights investor attention and the upcoming Q2 2026 earnings release on August 4, 2026, alongside strategic leadership appointments to accelerate growth.

The outlook remains positive given consistent earnings beats and high analyst buy ratings, though risks include negative cash flow trends and competitive pressures. Upside potential exists if the company maintains its earnings momentum, but investors should monitor cash flow improvements and execution of growth initiatives.